Drugs & Treatments

On The Horizon – MDV3100 in Men With Advanced Prostate Cancer Study Will Be Stopped Early and MDV3100 Offered to All Participants

It was announced yesterday that the Independent Data Monitoring Committee (IDMC) has informed the the pharmaceuticals, Medivation and Astellas of positive results from a planned interim analysis of the Phase 3 AFFIRM trial of MDV3100 in men with advanced prostate cancer previously treated with chemotherapy. The monitoring committee found that MDV3100, the first androgen receptor [...]

By |2017-10-19T10:51:56-04:00November 4th, 2011|Advanced Prostate Cancer, Chemo Therapy Failure, Clinical Trials, Clinical Trials, Drugs & Treatments, MDV3100, On The Horizon, Uncategorized|1 Comment
Read More

Androgen Receptor Genes Have An Opposite Effect In Prostate & Breast Cancers

A study at The Cleveland Clinic has discovered that a gene – known as an androgen receptor (AR) is present in both breast and prostate cancers, but the gene has opposite effects on these diseases. The AR gene promotes prostate cancer when the gene is “turned on,” but in breast cancer the AR gene promotes [...]

By |2017-10-19T10:51:56-04:00November 2nd, 2011|Advanced Prostate Cancer, Drugs & Treatments, General Information, genetics, Research, Uncategorized, Understanding APC|0 Comments
Read More

The Role of BRCA2 Mutations in Aggressive Prostate Cancer

According to research published today in the British Journal of Cancer, routine testing for a faulty BRCA2 gene (Kote-Jarai Z et al, BRCA2 is a gene contributing to young onset prostate cancer: implications for genetic testing in prostate cancer patients British Journal of Cancer (2011) doi:10.1038/bjc.2011.383) in men under 65 years with prostate cancer could [...]

By |2011-11-01T11:53:48-04:00November 1st, 2011|Advanced Prostate Cancer, BRCA2, Drugs & Treatments, General Information, genetics, PARP inhibitors, Research, Uncategorized, Understanding APC|1 Comment
Read More

Alpha Blockers Linked to Prostate Cancer Relapse

A retrospective study has just been published that shows that the risk of experiencing a biochemical recurrence (PSA recurrence) after radical prostatectomy to treat prostate cancer increased significantly in men who received alpha blockers for lower urinary tract symptoms (LUTS) after surgery. When compared to men who did not receive alpha blockers, those who did [...]

By |2017-10-19T10:51:57-04:00October 26th, 2011|Advanced Prostate Cancer, Drugs & Treatments, General Information, Uncategorized, Understanding APC|0 Comments
Read More

The Really Big Factor in Prostate Cancer Deaths Is Age – Can Rationing Save Money?

Is it a subtle form of healthcare rationing with the goal of saving money at the expense of lives? Maybe that is what is going on. Older men are not economically as valuable to society as other individuals, in many people’s eyes they are actually a burden. Can a solution to the problem be to [...]

By |2017-10-19T10:51:57-04:00October 25th, 2011|Advanced Prostate Cancer, Drugs & Treatments, End-Of-Life, Politics of Cancer, Uncategorized, Understanding APC|0 Comments
Read More

Attacking Androgen Receptor Signaling In Castrate Resistant Prostate Cancer

Advanced prostate cancer eventually progresses and becomes castration resistant (CRPC) despite the fact that it is exquisitely sensitivity to androgen deprivation therapy. There has been recent evidence that prostate cancer progression at the CRPC stage is still mediated by androgen receptor signaling, so it seems that subsequent androgen receptor targeting may further contribute to disease [...]

By |2017-10-19T10:51:57-04:00October 20th, 2011|abiraterone acetate, Advanced Prostate Cancer, Drugs & Treatments, Hormone Therapy, MDV3100, On The Horizon, TAK700, Uncategorized, Understanding APC|0 Comments
Read More

On The Horizon – Some More Information & An Update On MDV3100

Many of us are aware of the newly approved drug Zytiga (abiraterone). It had demonstrated a survival advantage for men who are castrate resistant and failed chemotherapy. Zytiga was approved by the FDA in April and many of us with advanced prostate cancer have been taking advantage of the drug. You can learn more about [...]

By |2017-10-19T10:51:59-04:00October 16th, 2011|abiraterone acetate, Advanced Prostate Cancer, Chemo Therapy Failure, Clinical Trials, Clinical Trials, Drugs & Treatments, MDV3100, On The Horizon, Provenge, Uncategorized, Understanding APC|2 Comments
Read More

On The Horizon- Coming Soon – Radium-223 (Alpharadin) A Bone Targeted Treatment for Advanced Prostate Cancer that Extends Life

At the recent European Multidisciplinary Cancer Congress in Stockholm, Dr Chris Parker from The Royal Marsden Hospital presented results of the phase 3 ALSYMPCA trial that showed both delayed time to first skeletal-related event (SRE) AND an overall survival (OS) benefit for those men with advanced prostate cancer taking radium-223 (Alpharadin). The real significance of [...]

By |2011-10-04T15:33:19-04:00October 4th, 2011|abiraterone acetate, Advanced Prostate Cancer, Alpharadin (radium-223), bisphosphonates, Cabazitaxel, Chemo Therapy Failure, Clinical Trials, Clinical Trials, denosumab - Xgeva, Drugs & Treatments, On The Horizon, Uncategorized, Zometa|1 Comment
Read More
Go to Top